- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00921115
Anti-Hormone Therapy (With Anastrazole and Fulvestrant) Before Surgery to Treat Postmenopausal Women With Breast Cancer.
Combined Fulvestrant and Anastrozole as Neo-adjuvant Endocrine Therapy in Postmenopausal Women With Hormone Receptor Positive Invasive Breast Cancer
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Hormonal therapies are generally preferred treatments of breast cancer because they have minimal side effects. Hormone receptor positive breast cancer generally does not respond very well to chemotherapy, which has many side effects. Hormonal therapy with a single drug such as Anastrozole is the main type of treatment used to reduce the risk of cancer recurrence. Whether a combination of Anastrazole nad Fulvestrant is effective and feasible is not known. This study is being done to answer this question.
This is a phase II single arm study. Patients will have an Oncotype Dx performed and only if the recurrence score is low or intermediate, they would be eligible. Eligible patients will receive Anastrazole and Fulvestrant for 16 week.
Subjects will receive Anastrazole 1 mg po q day and Fulvestrant 500 mg IM, day 1, day 14, day 28 and thereafter once every 28 days on outpatient basis. On day 28, subjects will be evaluated for side effects and clinically and a needle core biopsy (optional) will be obtained. If there is increase in Ki 67 by 50%, subjects will be taken off the study. Response evaluation will occur every 28 days during outpatient clinic visits. All treatment will continue until 4 months when patients will undergo surgical intervention. After surgery, patients will be off study and will receive additional breast cancer therapy at the discretion of their treating physician. Patients who develop progressive disease on protocol will be removed from the study and will then be treated at the discretion of the treating physician. The protocol will be closed after the last accrued patient has had surgery.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Kansas
-
Kansas City, Kansas, United States, 66160
- University of Kansas Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion criteria
- Female patient > 18 years of age.
- Histologically proven invasive adenocarcinoma of the breast.
- Patients must be candidates for neoadjuvant treatment (Tumor size > 2cm and/or clinical N1 or N2).
- ER positive (> 10% of cells) and/or PgR positive (> 10% of the cells) and HER-2 negative disease (IHC 0 or 1+ and/or FISH negative, IHC 2+ and FISH negative)
Menopausal status
Patients must be post-menopausal as defined by one of the following criteria:
- Prior bilateral oophorectomy
- 12 months since LMP with no prior hysterectomy
- Patients > 55 years with prior hysterectomy
- Patients < 55 years of age and with a prior hysterectomy without oophorectomy, estradiol and FSH levels must be consistent with the patient being postmenopausal.
- Premenopausal or perimenopausal women who do not meet the postmenopausal criteria above are also eligible, but are required to undergo ovarian suppression with an LHRH agonist. Ovarian suppression can be initiated any time prior to or on day 1 of protocol therapy and must continue throughout protocol therapy.
- Performance status of 2 or better per SWOG criteria
- No prior chemotherapy or endocrine therapy for the current cancer diagnosis.
- If female of childbearing potential, pregnancy test is negative prior to initiation of ovarian suppression.
- Patients must be informed of the investigational nature of the study, and must sign an informed consent in accordance with the institutional rules.
- Oncotype Dx Recurrence Score </= 25.
Exclusion criteria
- Patients with metastatic disease.
- The presence of any other medical or psychiatric disorder that, in the opinion of the treating physician, would contraindicate the use of drugs in this protocol or place the subject at undue risk for treatment complications.
- Premenopausal without ovarian suppression.
- Pregnancy or lactation.
- Patients with concomitant or previous malignancies within the last 5 years, with the exception of adequately treated basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix.
- Patients with emotional limitations are excluded from study
- Platelets less than 100 x 109 /L
- Total bilirubin greater than 1.5 x ULRR
- ALT or AST greater than 2.5 x ULRR
- History of bleeding diathesis (i.e., disseminated intravascular coagulation [DIC], clotting factor deficiency) or long-term anticoagulant therapy (other than antiplatelet therapy).
- History of hypersensitivity to active or inactive excipients of fulvestrant (i.e. castor oil or Mannitol).
- Oncotype Dx Recurrence Score of >25.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arimidex + Faslodex
Patients will have an Oncotype Dx performed and if the RS is <25, they will receive Anastrazole and Fulvestrant for 16 weeks. On day 28, subjects will be evaluated for side effects and a needle core biopsy (optional) will be obtained. Response evaluation will occur every 28 days. All treatment will continue for 4 months followed by breast surgery. After surgery, patients will be off study and will receive additional breast cancer therapy per their treating physician. Patients who develop progressive disease on protocol will be removed from the study and treated by their treating physician. The protocol will be closed after the last accrued patient has had surgery. |
Fulvestrant IM on day 14 and on day 28 followed by day 28 of all subsequent cycles thereafter.
Treatment will be continued for a total of 4 cycles.
Other Names:
Anastrazole, 1mg by mouth every day of all 28 day cycles and continued for a total of 4 cycles
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pathologic Complete Response (PCR) Rate
Time Frame: 4 months
|
Pathologic complete response (PCR) rate with 4 months of neo-adjuvant combination endocrine therapy (Anastrazole and Fulvestrant).
|
4 months
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Qamar Khan, MD, University of Kansas Medical Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Skin Diseases
- Neoplasms
- Neoplasms by Site
- Breast Diseases
- Breast Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Hormone Antagonists
- Aromatase Inhibitors
- Steroid Synthesis Inhibitors
- Estrogen Antagonists
- Estrogen Receptor Antagonists
- Fulvestrant
- Anastrozole
Other Study ID Numbers
- 11595
- IRUSANAS0092 (Other Identifier: Astra Zeneca)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Invasive Breast Cancer
-
University Health Network, TorontoCompletedBreast Cancer Invasive Nos | Primary Invasive Breast CancerCanada
-
Dana-Farber Cancer InstituteBeth Israel Deaconess Medical Center; Hoffmann-La Roche; Brigham and Women's...TerminatedStage I Breast Cancer | Stage II Breast Cancer | Invasive Breast Carcinoma | Stage III Breast Cancer | Primary Invasive Breast CancerUnited States
-
Dana-Farber Cancer InstitutePfizerCompletedBreast Cancer Stage IV | Unresectable Locally Advanced Invasive Breast Cancer | Metastatic Invasive Breast CancerUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Active, not recruitingStage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-positive Breast Cancer | HER2-negative Breast Cancer | Invasive Lobular Breast Carcinoma | Invasive Ductal Breast CarcinomaUnited States, Puerto Rico
-
H. Lee Moffitt Cancer Center and Research InstituteAmgenActive, not recruitingBreast Cancer | Invasive Breast Carcinoma | Invasive Ductal Breast Carcinoma | Ductal CarcinomaUnited States
-
University of Illinois at ChicagoRecruitingBreast Cancer Female | Breast Cancer InvasiveUnited States
-
Stanford UniversityNational Institutes of Health (NIH)RecruitingBreast Cancer | Breast Cancer Non-invasive Breast CancerUnited States
-
University of California, IrvineCompletedInvasive Breast Cancer | Incident Breast Cancer
-
University Medical Center GroningenMartini Hospital GroningenRecruitingBreast Cancer | Breast Cancer InvasiveNetherlands
-
RenJi HospitalRecruitingBreast Cancer InvasiveChina
Clinical Trials on Fulvestrant
-
Genor Biopharma Co., Ltd.RecruitingLocally Advanced or Metastatic Breast CancerChina
-
Ontario Clinical Oncology Group (OCOG)AstraZenecaCompleted
-
Xuanzhu Biopharmaceutical Co., Ltd.RecruitingAdvanced Breast CancerChina
-
Ahon Pharmaceutical Co., Ltd.RecruitingAdvanced Breast Cancer | Female Breast CancerChina
-
Jiangsu Hansoh Pharmaceutical Co., Ltd.Recruiting
-
Fudan UniversityActive, not recruiting
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Completed
-
Roswell Park Cancer InstituteCompleted
-
Zhejiang Cancer HospitalRecruitingBreast Neoplasm FemaleChina
-
European Organisation for Research and Treatment...Breast International GroupTerminatedBreast CancerUnited Kingdom